• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Definitive Healthcare Corp.

    10/3/24 9:08:57 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology
    Get the next $DH alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Definitive Healthcare Corp.

     

    (Name of Issuer)

     

    Class A Common Stock, $0.001 par value

     

    (Title of Class of Securities)

     

    24477E103

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 24477E103

    (1) Names of Reporting Persons

      Irenic Capital Management LP  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐

    (3) SEC Use Only

    (4) Citizenship or Place of Organization

      Delaware  

    Number of Shares Beneficially Owned By Each Reporting Person With

      (5) Sole Voting Power: 0*
      (6) Shared Voting Power: 6,413,185*
      (7) Sole Dispositive Power: 0*
      (8) Shared Dispositive Power: 6,413,185*

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person

      6,413,185*

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

      ☐

    (11) Percent of Class Represented by Amount in Row (9)

      5.5%*

    (12) Type of Reporting Person

      IA

     

    * See Item 4 for additional information.

     

     

     

     

    CUSIP No. 24477E103

     

    (1) Names of Reporting Persons

     
      Irenic Capital Evergreen Master Fund LP  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐
      (b) ☐

    (3) SEC Use Only

     

    (4) Citizenship or Place of Organization

     
      Cayman Islands  

    Number of Shares Beneficially Owned By Each Reporting Person With

      (5) Sole Voting Power: 0*
      (6) Shared Voting Power: 6,413,185*
      (7) Sole Dispositive Power: 0*
      (8) Shared Dispositive Power: 6,413,185*

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person

      6,413,185*

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

      ☐

    (11) Percent of Class Represented by Amount in Row (9)

      5.5%*

    (12) Type of Reporting Person

      PN

     

    * See Item 4 for additional information.

     

     

     

     

    CUSIP No. 24477E103

    (1) Names of Reporting Persons

      Adam Katz  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐

    (3) SEC Use Only

    (4) Citizenship or Place of Organization

      United States of America  

    Number of Shares Beneficially Owned By Each Reporting Person With

      (5) Sole Voting Power: 0*
      (6) Shared Voting Power: 6,413,185*
      (7) Sole Dispositive Power: 0*
      (8) Shared Dispositive Power: 6,413,185*

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person

      6,413,185*

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

      ☐

    (11) Percent of Class Represented by Amount in Row (9)

      5.5%*

    (12) Type of Reporting Person

      IN

     

    * See Item 4 for additional information.

     

     

     

     

    CUSIP No. 24477E103

    (1) Names of Reporting Persons

      Andrew Dodge  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐

    (3) SEC Use Only

    (4) Citizenship or Place of Organization

      United States of America  

    Number of Shares Beneficially Owned By Each Reporting Person With

      (5) Sole Voting Power: 0*
      (6) Shared Voting Power: 6,413,185*
      (7) Sole Dispositive Power: 0*
      (8) Shared Dispositive Power: 6,413,185*

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person

      6,413,185*

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

      ☐

    (11) Percent of Class Represented by Amount in Row (9)

      5.5%*

    (12) Type of Reporting Person

      IN

     

    * See Item 4 for additional information.

     

     

     

     

    Item 1(a). Name Of Issuer:

     

    Definitive Healthcare Corp. (the “Company”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    492 Old Connecticut Path, Suite 401

    Framingham, MA 01701

     

    Item 2(a). Name of Person Filing:

     

    This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Irenic Capital Management LP, a Delaware limited partnership (“Irenic Capital”), (ii) Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership (“Irenic Evergreen Master Fund”), (iii) Adam Katz and (iv) Andrew Dodge, with respect to the shares of Class A Common Stock, $0.001 par value (the “Class A Common Stock”), of the Company held by Irenic Evergreen Master Fund. Irenic Capital is the investment manager of Irenic Evergreen Master Fund. Irenic Capital Management GP LLC (“Irenic Capital GP”), a Delaware limited liability company, is the general partner of Irenic Capital. Irenic Capital Evergreen Fund GP LLC (“Irenic Evergreen GP”), a Delaware limited liability company, is the general partner of Irenic Evergreen Master Fund. Adam Katz is the Chief Investment Officer of Irenic Capital and a managing member of each of Irenic Capital GP and Irenic Evergreen GP. Andrew Dodge is the Director of Research of Irenic Capital and a managing member of each of Irenic Capital GP and Irenic Evergreen GP.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The business address of each of Irenic Capital, Irenic Evergreen Master Fund, Irenic Capital GP, Irenic Evergreen GP and Messrs. Katz and Dodge is 767 Fifth Avenue, 15th Floor, New York, NY 10153.

     

    Item 2(c). Citizenship:

     

    Irenic Capital is a Delaware limited partnership. Irenic Evergreen Master Fund is a Cayman Islands limited partnership. Irenic Capital GP and Irenic Evergreen GP are Delaware limited liability companies. Messrs. Katz and Dodge are citizens of the United States of America.

     

    Item 2(d). Title of Class of Securities:

     

    Class A Common Stock

     

    Item 2(e). CUSIP No.:

     

    24477E103

     

    Item 3. If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

     

    Not Applicable.

     

     

     

     

    Item 4. Ownership:

     

    As reported in the cover pages to this report, the ownership information with respect to each of Irenic Capital, Irenic Evergreen Master Fund and Messrs. Katz and Dodge is as follows:

     

    (a) Amount Beneficially Owned: 6,413,185*
    (b) Percent of Class: 5.5%*
    (c) Number of Shares as to which such person has:  
      (i) sole power to vote or to direct the vote: 0*
      (ii) shared power to vote or to direct the vote: 6,413,185*
      (iii) sole power to dispose or to direct the disposition of: 0*
      (iv) shared power to dispose or to direct the disposition of: 6,413,185*

     

    * Irenic Capital is the investment manager to Irenic Evergreen Master Fund. Irenic Capital GP is the general partner of Irenic Capital and Irenic Evergreen GP is the general partner of Irenic Evergreen Master Fund. Adam Katz is the Chief Investment Officer of Irenic Capital and a managing member of each of Irenic Capital GP and Irenic Evergreen GP. Andrew Dodge is the Director of Research of Irenic Capital and a managing member of each of Irenic Capital GP and Irenic Evergreen GP.

     

    As of September 30, 2024, Irenic Evergreen Master Fund held 6,413,185 shares of Class A Common Stock. As of September 30, 2024, Irenic Capital and Messrs. Katz and Dodge may be deemed to beneficially own 6,413,185 shares of Class A Common Stock held by Irenic Evergreen Master Fund.

     

    The reported beneficial ownership percentage is based upon 117,123,112 shares of Class A Common Stock issued and outstanding as of August 1, 2024, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    Not Applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10. Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      October 3, 2024
         
      IRENIC CAPITAL EVERGREEN MASTER FUND LP
         
      By: Irenic Capital Management LP, its Investment Manager
         
      By: /s/ Joshua Brodman
      Name: Joshua Brodman
      Title: Chief Compliance Officer

     

      IRENIC CAPITAL MANAGEMENT LP
         
      By: /s/ Joshua Brodman
      Name: Joshua Brodman
      Title: Chief Compliance Officer

     

      /s/ Adam Katz
      Adam Katz
       
      /s/ Andrew Dodge
      Andrew Dodge

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

    Exhibit Index

     

    Exhibit

     

    1. Joint Filing Agreement, dated as of October 3, 2024, by and between Irenic Capital Management LP, Irenic Capital Evergreen Master Fund LP, Adam Katz and Andrew Dodge.

     

     

    Get the next $DH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DH

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    12/20/2024$5.00Equal-Weight
    Stephens
    9/17/2024$7.00Buy
    BTIG Research
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    5/8/2024$11.50 → $9.00Overweight → Equal-Weight
    Morgan Stanley
    1/17/2024Buy → Hold
    Needham
    1/5/2024Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $DH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Definitive Healthcare Corp.

      SCHEDULE 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      5/15/25 4:36:54 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SCHEDULE 13G filed by Definitive Healthcare Corp.

      SCHEDULE 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      5/9/25 12:25:52 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 10-Q filed by Definitive Healthcare Corp.

      10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:22:09 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Financials

    Live finance-specific insights

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

      FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

      2/27/25 4:05:53 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Booth Richard Douglas covered exercise/tax liability with 7,873 shares, decreasing direct ownership by 1% to 652,630 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:10 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • EXECUTIVE CHAIRMAN Krantz Jason Ronald covered exercise/tax liability with 18,795 shares, decreasing direct ownership by 2% to 1,106,362 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:14 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • CHIEF OPERATING OFFICER Shamsuddin Kate Marie covered exercise/tax liability with 4,595 shares, decreasing direct ownership by 0.65% to 699,902 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:11 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

      FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of

      4/4/25 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Definitive Healthcare downgraded by BTIG Research

      BTIG Research downgraded Definitive Healthcare from Buy to Neutral

      5/9/25 8:41:31 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare downgraded by Barclays with a new price target

      Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

      1/13/25 7:41:23 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Stephens initiated coverage on Definitive Healthcare with a new price target

      Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00

      12/20/24 7:31:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      11/12/24 11:54:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      10/3/24 9:08:57 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Definitive Healthcare Corp. (Amendment)

      SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      2/14/24 4:00:33 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Leadership Updates

    Live Leadership Updates

    See more
    • Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

      FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

      5/28/24 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

      Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

      11/28/23 5:00:00 PM ET
      $DH
      $GDRX
      Computer Software: Prepackaged Software
      Technology
      EDP Services
    • Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

      FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

      10/5/23 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology